Why the study?
The initial approach to chronic coronary syndrome requires discussing whether to prioritize initial optimal medical therapy or an initial invasive myocardial revascularization procedure.
Does initial invasive management reduce death or major adverse cardiovascular events compared to initial optimal medical therapy in patients with high-risk chronic coronary syndrome?
Does initial invasive management reduce death or major adverse cardiovascular events compared to initial optimal medical therapy in patients with high-risk chronic coronary syndrome?
Answers are grounded in this paper and cite their sources.
This narrative review synthesizes evidence from landmark clinical trials supporting initial optimal medical therapy over routine early invasive revascularization for most patients with high-risk chronic coronary syndrome, reserving early invasive management for refractory angina, left main disease, or significant left ventricular dysfunction.
RESUMEN La definición de síndrome coronario crónico de alto riesgo varía según la prueba no invasiva empleada para evidenciar isquemia, lo que se consigue a través de un aumento del trabajo miocárdico y la demanda de oxígeno, generados con el uso de fármacos o el ejercicio. El abordaje inicial nos sumerge en la discusión de contextualizar en qué casos priorizar la terapia médica óptima inicial, frente al manejo invasivo inicial, con el objetivo de lograr la revascularización miocárdica. Este aspecto central será desarrollado en esta revisión, tomando en cuenta diversos estudios realizados hasta la fecha, en los que el manejo invasivo inicial no ha demostrado ser superior a la terapia médica óptima inicial en resultados clínicos relevantes como muerte o eventos adversos cardiovasculares mayores.
No takes yet. Share an insight, caveat, or question.
Rueda et al. (2020) conducted a review in High-risk chronic coronary syndrome. Initial optimal medical therapy (conservative management) vs. Initial invasive management (percutaneous coronary intervention or coronary artery bypass grafting) plus medical therapy was evaluated on All-cause mortality, myocardial infarction, or major adverse cardiovascular events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: